G López-Abente, A Escolar
Tobacco consumption is the principal known risk factor for urinary bladder cancer. This relation has been analytically characterised on the basis of diVerent aspects of the smoking habit (inhalation pattern, tobacco type, duration). 1 2 Other risk factors described for bladder cancer are occupation and coVee consumption, 1 3-5 although results for coVee consumption have been contradictory. The important role of cigarette smoking as a confounding factor has been one of the traditional diYculties hindering research into the association between coVee consumption and bladder cancer. In general, studies that have restricted analysis to non-smokers show a weak positive association for coVee consumption, with no eVect observed among the smoker stratum. This latter finding is indicative that coVee drinking could have an "attenuator" eVect on the risk associated with tobacco use.
In this report, we present the results of a new analysis of the association between cigarette smoking and bladder cancer, in which coVee drinkers were separated from non-coVee drinkers, an aspect that, to our knowledge, has never been published until now.
Methods
Data came from a multicentre case-control study, the design and results of which have been published elsewhere. 2 5 In short, all new cases of bladder cancer diagnosed in the period, January 1985 to March 1986 (incident cases) and all those diagnosed in the period, 1983-1984 (prevalent cases), were included. Cases were selected from 12 general hospitals spread throughout five Spanish provinces (Barcelona, Madrid, Cádiz, Guipúzcoa and Vizcaya) and totalled 497 histologically confirmed cases of carcinoma, polyps and papilloma of the bladder, occurring in men and women under age 80 years at diagnosis and resident in the province where the hospital was located. Two controls (hospital and population), matched by sex and age ( ± 5 years), were included for each case, making a total of 583 hospital and 530 population controls.
Interviews were carried out at subjects' homes by trained interviewers who had not been informed as to interviewee case/control status. The questionnaire contained sections dealing with occupational history, tobacco use, passive exposure to tobacco smoke, diet, coVee consumption, use of artificial sweeteners, consumption of analgesics and past history of diabetes, lithiasis and urinary infections. In the section dealing with tobacco use, a complete history was obtained on cigarette, cigar and pipe tobacco consumption, by profiling levels of consumption, tobacco brand, type and characteristics (black, blond, filter and low tar) and duration of all periods in which use occurred. 2 5 Non-coVee drinkers were defined as those drinking fewer than two cups a week. A logistic regression analysis was run to estimate the odds ratio (OR) for each variable. All risk estimates shown have been adjusted for age, sex and place of residence. Table 1 sets out the distribution of controls with respect to cigarette and coVee consumption. From this distribution, it will be seen that cigarette and coVee consumption are closely linked, proving very similar in both types of controls.
Results
In table 2, estimation of the eVect of cigarette smoking is shown separately for the two constituent coVee consumption strata. Among non-coVee drinkers, 30 cases (91%) were smokers, while among controls the figure was 58%. The eVect of cigarette smoking on bladder cancer risk was systematically estimated to be more than double among non-coVee drinkers than among coVee drinkers. The plateau in the eVect of smoking over 10 cigarettes/day observed in the initial analysis 2 was maintained in both strata, as was the dose response eVect for the duration of the habit. The results are similar when the two control groups (hospital and population) are analysed separately.
Discussion
The results suggest that the relative risk of suffering bladder cancer among cigarette smokers who do not drink coVee may be far higher than that published so far and that exposure to coffee may thus have an "attenuator"' eVect on the risk associated with tobacco use. None the less, odds ratios of about 3 were also seen for smoking among coVee drinkers. Studying non-coVee drinkers by strata is difficult in that the two habits are closely linked, and there is a paucity of cases at the reference level (that is, never smokers). This leads to lack of precision in the estimations. The risk none the less remains very high when a reference level is established composed of non-smokers and ex-smokers.
The role of caVeine in somatic damage induced by carcinogenic agents has been the subject of several studies. In vitro studies indicate that caVeine may have a booster eVect on the cytotoxic eVect of certain compounds 6 (for example, DNA intercalating agents). In addition results have been published that point to the role of coVee consumption as eVect modifier of other exposures on the risk of cancers with ras mutations. 7 In contrast, other studies discuss its possible protective eVect, by acting as an antimutagenic through formation of complex compounds. [8] [9] [10] All authors are however unanimous when it comes to establishing its influence on DNA repair and damage mechanisms. Furthermore, the toxicity of caVeine seems to be lower among smokers.
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CaVeine moreover reduces the number of mutations induced in vitro by a carcinogenic aromatic amine (MeIQx), possibly because of an alteration of the spectrum of enzymes involved in its activation. 12 Among these enzymes is cytochrome P4501A2 (CYP1A2). CaVeine acts as an inductor of CYP1A2 activity, which may be related to risk of bladder cancer through metabolic activation of aromatic amines and formation of compounds that in turn lead to formation of DNA adducts. 13 High consumption of coVee (more than four cups of coVee per day) 13 has been observed to lead to such induction in N-oxidation activity, dependent-among other factors-on CYP1A2.
Recently published results suggest the presence of complex modifying eVects phenomenon of the cigarette smoking and coVee consumption in colon cancer 14 and between alcohol and coVee consumption in liver cancer. 15 In addition, studies in laboratory animals have shown a protector eVect of the caVeine in rats treated with nicotine derived carcinogens 16 and the inhibition of the cell proliferation and metastatic behaviour of melanoma cancer cells. 17 The results of our study suggest that the risk of suVering bladder cancer among cigarette smokers may be far higher than that published to date, and that coVee consumption exercises a modulating role, aVording a certain protection against the carcinogenic risk associated with smoking. It would be of great interest to evaluate CYP1A2 and acetilisation phenotype activity, along with possible coVee induced modification of tobacco related eVects, in future studies on bladder cancer and studies on any other tumour sites that have considered both risk factors. Non-coVee drinkers exclude ex-coVee drinkers.
